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a b s t r a c t
In residue analysis of veterinary drugs in foodstuff, matrix effects are one of the most critical points. This
work present a discuss considering approaches used to estimate, minimize and monitoring matrix
effects in bioanalytical methods. Qualitative and quantitative methods for estimation of matrix effects
such as post-column infusion, slopes ratios analysis, calibration curves (mathematical and statistical
analysis) and control chart monitoring are discussed using real data. Matrix effects varying in a wide
range depending of the analyte and the sample preparation method: pressurized liquid extraction for
liver samples show matrix effects from 15.5 to 59.2% while a ultrasound-assisted extraction provide
values from 21.7 to 64.3%. The matrix inﬂuence was also evaluated: for sulfamethazine analysis, losses of
signal were varying from 37 to 96% for ﬁsh and eggs, respectively. Advantages and drawbacks are
also discussed considering a workﬂow for matrix effects assessment proposed and applied to real data
from sulfonamides residues analysis.
& 2014 Elsevier B.V. All rights reserved.
1. Introduction
Food containing veterinary drug residues above maximum
residue limit (MRL) is of major concern, since it is related directly
to public health as well as international trade relationships. The
demand in food regulatory control has expanded dramatically in
recent decades, and residues surveillance became an important
factor to be considered in international trade of commodities [1,2].
In Brazil, veterinary drug and pesticide residues analysis in animal
(and also in vegetable) products are under the Ministry of Agriculture,
Livestock and Supply (MAPA) management [3]. Routine analysis
and methods development and validation are attributed to MAPA
ofﬁcial laboratories network – National Agricultural Laboratories
(Lanagro) – and MAPA accredited private laboratories [4]. MAPA’s
demand on method development and validation in residue analysis
has been increased in the last decade due to the increased role of the
Brazilian livestock products in national and international markets and
meanly to ensure that the products traded are compliant with the
safety and quality criteria required by consumers [4,5]. Wherefore, our
laboratory has absorbed one important fraction of this demand in
developing, validating, and submitting for accreditation methods for
analysis of antimicrobial and non-antimicrobial residues in different
matrices, such as milk and edible tissues of different animal species
including cattle, pork, poultry, and even ﬁsh [6–10]. For these
purposes, international guidelines, such as Commission Decision
2002/657/EC concerning the performance of analytical methods and
the interpretation of results, and others from the US Food and Drug
Administration (FDA) and the International Conference on Harmoni-
zation (ICH), are used in order to obtain methods validated according
to the most stringent international criteria [11–14]. Within this issue,
especial attention is paid to matrix effect (ME), which is a fundamental
parameter to be determined, assessed and minimized especially when
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liquid chromatography–mass spectrometry (LC–MS) and/or tandem
mass spectrometry (LC–MS/MS) methods are used [15–19]. The
conceptualization of this phenomenon has been comprehensively
reviewed by a number of authors [15,16,20,21]. Brieﬂy, ME is related
to the alteration of ionization efﬁciency in the ionization source by the
presence of coeluting substances: the occurrence of endogenous
substances originally present in the sample itself and that remains
in the ﬁnal extract, are appointed as the major source. A wide scope of
molecules can lead to signal suppression or enhancement, especially
when occurs in high concentration in the extract and elute in the same
retention time window than the analyte [22]. A secondary cause are
substances not originally present in the samples but able to migrate to
extracts during sample preparation process as polymer and phthalates
or material released by stationary phases, in bulk or in solid phase
extraction (SPE) cartridges, for instance [20]. Normally, this alteration
affects dramatically the method accuracy and precision and has been
regarded as a critical validation item by most guidelines consulted.
However, there is no consensus on how this phenomenon should be
assessed during method validation. Beside, different experienced
approaches of ME evaluation, based on procedures published in the
scientiﬁc literature such as post-column infusion, calibration curves
comparison, quantitative estimation based in standards, spiked sam-
ples and matrix-matched control comparison and control charts
evaluation, has been experienced [23–27].
Although the knowledge on ME in mass spectrometry analysis
has been improved in recent years, only few practical approaches
has been reported for routine analysis [28–31]. In the present
work, practical approaches to detect and estimate the occurrence
of ME in qualitative and quantitative terms in LC–MS/MS methods
for veterinary drugs residues analysis are presented and discussed.
Tools for monitoring ME along the execution of routine methods
are also reported. Without the purpose to exhaust the issue, the
present study is proposed as a walkthrough based in relatively
simple and easy techniques to be applied to analytical chemistry
laboratories to deal with the critical theme of matrix effects in
residues analysis.
2. Materials and methods
2.1. Analytical standards and reagents
Analytical standards with high purity (Z99%) were obtained
from Sigma-Aldrich (St Louis, MO, USA) namely sulfamerazine (SMR),
sulfamethazine (SMZ), sulfamethoxazole (SMA), sulfamethoxypyri-
dazine (SMPZ), sulfadiazine (SDZ), sulfapyridine (SPY), sulfadi-
methoxine (SDMX), sulfaguanidine (SGA), sulfacetamide (SCA),
sulfabenzamide (SBZ), sulﬁsomidin (SIM), sulfamethizole (SMTZ),
sulfaquinoxaline (SQX), sulfathiazole (STZ), sulfaisoxazole (SIX) and
sulfadoxin (SDX). The metabolite N4-acetyl-sulfamerazine (N4-SMR)
and the isotopically labelled compounds d4-sulfamethoxazole (d4-
SMA), d4-sulfamethazine (d4-SMZ) and d4-sulfadiazine (d4-SDZ), used
as surrogate and/or internal standards, were purchased from Toronto
Research Chemicals (North York, Ontario, Canada).
Methanol (MeOH), acetonitrile (ACN), hexane and acetone of
HPLC-grade were supplied by J. T. Baker (Deventer, The Nether-
lands). Diatomaceous earth was supplied by Agilent Technologies.
Acetic acid and water (HPLC grade) were purchased from Merck
(Darmstadt, Germany).
Individual stock standard solutions were prepared in MeOH:
acetone (50:50) at 1 mg mL1 and stored at 4 1C until use.
Standard solutions of the mixtures of all compounds in appro-
priate concentrations were prepared by stock solutions dilutions
using MeOH or acetone. Aliquots of each stock standard solution
were diluted to obtain ﬁnal concentrations of 10 mg mL1 and
1 mg mL1 and were stored at 20 1C.
2.2. Samples and sample preparation
Liver of different food production animals, chicken eggs, and
ﬁsh muscle were obtained from Federal Inspection Service (SIF) or
collected from treated animals in a farm. Liver and muscle samples
were manual and ﬁnely chopped and homogenized in order to
avoid slurring. Egg samples were manual and gently homogenized
in order to avoid protein denaturation. After these processes, all
samples were stored at 20 1C before extraction step.
Liver and ﬁsh samples were extracted by two different methods
based on pressurized liquid extraction (PLE) and by ultrasounds-
assisted extraction (US). A detailed discussion about these meth-
ods and validation results were submitted to publication. For PLE,
an ASE 350 accelerated solvent extractor (Dionex, Sunnyvale, CA,
USA) was used. Prior to extraction, d4-SMA, d4-SMZ and d4-SDZ
were added as surrogate standards in a concentration of
100 ng g1. Samples (0.5 g) were mixed into the PLE cells with
diatomaceous earth as dispersing agent. Prior to extraction, the
cells were submitted to a clean up method in order to remove
lipids from the samples using hexane as solvent. PLE parameters
were as follows: temperature 60 1C, 4 cycles of 5 min each one.
Total ﬂush volume of 80% and 300 s of purge with nitrogen ﬂow
were applied.
After that, the same PLE cells were submitted to a second
extraction process using ACN with 0.2% acetic acid as extraction
solvent. In this case, the extraction temperature was optimized at
90 1C. A preheating period of 8 min was selected and 3 cycles of
7 min each were carried out. A total ﬂush volume of 80% and 60 s
of purge with nitrogen ﬂow were applied. Pressure was set at
1500 psi as it has been demonstrated that this parameter is not
decisive in PLE.
The extracts were maintained in freezer by 1 h (at 18 1C) in
order to promote protein precipitation. Following, samples were
centrifuged at 1500 g for 10 min in a 5810R centrifuge (Eppen-
dorf). The supernatant was evaporated at 40 1C under nitrogen
ﬂow using a Turbo-Vap system (Zymark) until dryness. Extracts
were redissolved in 1.0 mL of mobile phase mixture (water-ACN,
85:15) and transferred to a HPLC vial.
In ultrasound-assisted extraction, samples (0.5 g) were
weighted in 15 mL polypropylene tubes and spiked as described
for the PLE method. Following, 10 mL ACN were added and tubes
were mixed in a mechanical vortex by 10 s. Afterwards all samples
were placed into an ultrasonic bath for 1 h. and then stored in
freezer (18 1C) for 1 h. to promote protein precipitation. Then,
samples were centrifuged at 1500 g for 10 min. Supernatant was
brought to dryness at 40 1C under a gentle nitrogen stream. The
extracts were redissolved in 2.0 mL of the mobile phase mixture.
An aliquot of 2 mL of hexane was added to remove the fat content.
Afterwards, tubes were mixed in a vortex for 5 s followed by
centrifugation (3500 rpm for 10 min). The lower layer was care-
fully transferred to a HPLC vial.
Sulfonamides analysis in eggs samples was performed as
described elsewhere [32]. Brieﬂy, samples were extracted with
ACN and concentrated before reconstitution with mobile phase.
2.3. Instrumentation
LC analysis was performed with a Symbiosis™ Pico System
(Spark Holland, Emmen, The Netherlands), equipped with a HPLC
system consisting of an Alias™ autosampler, a loop injector and
two binary pumps with a four-channel solvent selector for each
one. Chromatographic separation was performed using a HPLC
column Purosphers STAR (C18, ec, 1504.6 mm, 5 mm) preceded
by a guard column with the same packing material. The ﬂow rate
was set to 0.2 mL min1, being eluent (A) HPLC grade water
acidiﬁed with 10 mM of formic acid, and eluent (B) ACN with
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10 mM of formic acid. The elution gradient started with 25% of
eluent (B), increasing to 80% in 10 min and to 100% in 11 min.
During the next 2 min the columnwas kept at 100% (B), readjusted
to the initial conditions in 3 min and equilibrated for 7 min. MS/
MS analyses were carried out in a 4000 QTRAP hybrid triple
quadrupole-linear ion trap mass spectrometer (Applied Biosys-
tems, Foster City, CA, USA) equipped with a turbospray ionization
source (ESI) working in the positive mode (ESIþ).
For ﬁsh and egg analysis, the LC–MS/MS system was an Agilent
1100 series LC (Santa Clara, CA, USA) with a quaternary pump, a
vacuum degasser, and an auto sampler, coupled with an API 5000
triple quadrupole mass spectrometer (Applied Biosystems, Foster
City, CA, USA) with an electrospray ionization source (ESI).
The optimization of the MS/MS experimental conditions was
performed in previous studies and are presented in our work
published elsewhere (OR: in this same issue) [33]. For increased
sensitivity and selectivity, MS/MS data acquisition was performed
in the selected reaction monitoring (SRM) mode, recording the
two most intense transitions from the precursor ions to the
product ions.
2.4. Post-column infusion method
Post-column infusions of individual standards into the MS
system were performed to verify the ME of the extracts obtained
for all methods, in order to verify if the whole extract or some
elution fraction of the extract cause signal suppression/enhance-
ment. This procedure was based on the experiments described by
Bonﬁglio et al. [23]. Brieﬂy, blank samples extracted by the above-
mentioned methods were injected into the LC–MS/MS system
under the chromatographic conditions optimized for each meth-
odology. For each injection, a standard solution of individual
compound was infused into the MS system using an infusion
pump, at a ﬂow rate of 10 μL min1, through a tee-joint installed
post-column. Standard solution concentration was 100 ng mL1.
ME were evaluated observing signal attenuation or signal
enhancement on the response of the infused analyte.
2.5. Calibration curves evaluation method
A calibration curve was prepared using standard solutions
diluted in pure solvent or in mobile phase (external Standard
calibration curve or “S”). A second calibration curve was prepared
spiking a blank matrix and following with the extraction and/or
cleanup procedure (Recovery calibration curve or “R”). Finally, a
third calibration curve was made using a extract of a blank sample,
which was submitted to the whole extraction and/or cleanup
procedure and was spiked with standard solution at the end of the
protocol, generally in the ﬁnal dilution, immediately before injec-
tion (Tissue Standard calibration curve (matrix-matched) or “TS”).
These calibration curves were prepared with the same number of
points or replicates to obtain the same expected concentration in
the three kinds of curve. Usually, the MRL is the central point and
are constructed with a minimum of 6 point. For a MRL value of
100 μg kg1 (as in the case of sulfonamides in liver), calibration
curves comprehends 0, 25, 50, 100, 150 and 200 μg kg1 levels. All
curves were prepared and analyzed in the same batch for a more
accurate comparison. After analysis, the curves were plotted and
inspected visually and statistically.
Alternatively, ME was evaluated using slope ratios comparison
according to the approach proposed by Romero-Gonzáles et al.
[34] and Sulyok et al. [35] in a modiﬁed application of the
quantitative approach of Matuszewski et al. [24]. Slopes are
compared between each pair of curves obtained in the linear
calibration curves prepared by spiking mobile phase (S), blank
sample (R), and extract of blank sample (TS). Slope ratios below
0.9 or above 1.1 were associated with ion suppression and ion
enhancement, respectively. For values inside that range, ME was
considered negligible.
To differentiate between extraction efﬁciency and matrix-
induced signal suppression/enhancement, the slope ratios of the
linear calibration functions were calculated to yield the recovery
(RE), the signal suppression/enhancement due to ME and the
relative recovery, i.e. the recovery of the extraction step (RER) as
follows:
REð%Þ ¼ 100 slopespikedsamples=slopeliquidstandards ð1Þ
MEð%Þ ¼ 100 slopematrixmatched standard=slopeliquidstandards ð2Þ
RERð%Þ ¼ 100 slopespikedsamples=slopematrixmatched standard ð3Þ
2.6. Matrix effect quantitative estimation
The quantitative estimation of a ME, when present, was
performed using a modiﬁcation of the equations previously
proposed by Matuszewski et al. [24]. This procedure allows
determination of the ME along with the RER and overall “process
efﬁciency” or method overall recovery (RE) by comparing the
absolute peak areas of 3 sets of samples. Set A is composed by
standard solutions (S). Set B is composed by samples spiked after
extraction (TS) and set C is prepared with samples spiked before
extraction (R). Since the values have been obtained, ME, RER, and
RE values can be calculated as follows:
MEð%Þ ¼ ðB=A 100Þ100 ð4Þ
RERð%Þ ¼ C=B 100 ð5Þ
REð%Þ ¼ C=A 100¼ ðME RERÞ=100 ð6Þ
2.7. Control chart
Control charts are a useful tool for the monitoring of the
analytical method behavior along with-in-batch and batch-to-
batch variations including those due to ME. Within this purpose,
for each analysis batch, 6 quality control samples (QC) spiked at
the MRL concentration level for all compounds analyzed in each
method were obtained. These QC samples, as described above, are
composed by 3 samples spiked after (TS) and 3 samples spiked
before extraction (R). Analyte peak area of each QC sample plus
standards in pure solvent are plotted in a spreadsheet using Excel
software. The cells include a formula to provide average, relative
standard deviation and the upper and lower limits for ME,
calculated according to the control chart parameters.
3. Results and discussion
As aforementioned, there is no consensus on howME should be
evaluated during method validation, neither on the criteria that
should be adopted in establish when these effects are or not
occurring [36]. However, according to recent literature, two main
procedures have been used to determine ME on LC–ESI–MS/MS
analysis: post-column infusion, which is a dynamic technique that
provides qualitative information on where ME occur along the
chromatographic run; and post extraction addition, which is a
static technique that quantitatively provides the ME degree at the
analyte retention time [20,37]. The last technique has been
preferentially used to evaluate and compare ME of different
matrices in terms of relative ME. In order to evaluate the most
reported approaches to ME estimation, data of two in-house
developed and validated methods were used as an example.
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3.1. Case study: Determination of sulfonamides (SAs) in liver, muscle
and ﬁsh using two extraction procedures
Two extraction methods were developed and validated for
analysis of SAs residues in liver, muscle and ﬁsh. The complete
development, optimization and validation data for both methods
were recently submitted to publication. Both, the PLE and the US
methods were previously evaluated by their potential ME using all
the described approaches.
3.2. Post-column infusion method
First, blank extracts from each extraction method were injected
in a post-column apparatus for comparison with pure mobile
phase in order to evaluate the variation of the standards mixture
signal.
The chromatographic separation of SAs was achieved using a
modiﬁcation of the method published elsewhere [33,38]. Some
SAs had very similar chromatographic retention time (coeluting),
but were well resolved as individual peaks in the MS/MS SRM
mode. The detailed optimization and discussion about the chro-
matography method are presented in our report published in that
same issue.
To evaluate ME, ﬁrst we investigated if the extraction methods
could contribute with co-extractive substances that might suppress
selectively the different temporal regions of the chromatogram.
As can be observed in Fig. 1, both PLE and US extracts presented
signal suppression in some regions of the chromatogram. This
suppression effect is more intense in the 5–6 min region. Mobile
phase signal (MP, grey line) shows a standard solution infused in a
post-column “T” connection, over a mobile phase injection. PLE
(black line) and US (dashed black line) represent the signal of the
respective blank extracts. The standard solution was a mixture of
all analytes at a concentration level of 100 ng mL1. Any line
represents a TIC signal for all monitored SRM transitions (436). TS
signal is a TIC chromatogram for a blank sample spiked at
100 ng mL1 injected in normal mode. The signal was multiplied
by a factor of 20 times for a better comparison with the post-
column infusion chromatograms. PLE and US showed very similar
matrix effects over the standard signal. In the region 11–22 min
both signals were virtually overlaid. In summary, analytes do not
elute in the most critical suppression zones. Thus, the chromato-
graphic conditions could be used without modiﬁcations.
3.3. Calibration curves approach
As explained before, the use of calibration curves to estimate
ME can be performed in many ways. Herein, examples of each
interpretation mode are demonstrated.
3.4. Graphical plot—Visual and statistical analysis
Once the 3 curves are analyzed and plotted, the following
situations are considered:
Situation 1. A similar slope, non-similar intercepts. Similarity
between slopes show that matrix do not interfere in the linearity
of the responses. The difference between intercepts is given by the
losses caused by the sample preparation process. It is expected a
lower response for R curve. If TS and S curve could be overlapped,
there is no ME. If those curves have non-similar behaviour, ME is
present, but it is affecting only the signal, not the linearity. Any
kind of curve can be used in this method, if an appropriate
correction is applied to adjust response losses. Fig. 2 shows an
example of this situation.
Situation 2. Non-similar slopes: linearity is distinct between
curves. If TS and R curves had similarity in the slopes, this means
that the presence of the matrix itself change the responses. In this
case, only TS or R calibrations curves may be used in this method.
Fig. 3 gives an example.
Situation 3. TS and S curves are totally overlapped. There is no
ME. However, if R curve shows differences in intercept and slope,
this means that sample preparation process change signiﬁcantly
the response. Thus, R curves may be used. See Fig. 4 for an
experimental data example.
Situations 4. All curves are perfectly overlapped. No ME and
recovery equals or very closely to 100%. Presumably this is just a
theoretical possibility.
Fig. 1. Total ion chromatograms of post-column experiments. Continuous black line is a pressurized liquid extraction (PLE) blank extract; dashed black line is a ultrasound-
assisted extraction (US) extract; grey line is mobile phase injection (MP) and the lower chromatogram in bold black line is a spiked tissue extract injected without post-
column infusion in order to identify the elution window of the target analytes (TS).
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In some cases, a matrix can exhibit high heterogeneity from
sample to sample, which can cause signiﬁcant alterations in ME
[39]. This situation must be also evaluated in method development
and validation. The simple superposition of plot is useful to
distinguish between each calibration curve. But in some cases
statistical analysis must be performed to elucidate the variation.
For slope variation values, a F-test is applied. If FcaloFtab, the F-test
is not signiﬁcant (5% signiﬁcance level), and it can be considered
that the variances are similar.
For instance, from statistical comparison for sulfamerazine
analysis in liver using matrix-matched calibration curves prepared
by 2 distinct extraction methods (PLE and US) we obtained
FcaloFtab (Fcal¼0.10 and Ftab¼12.22 (0.05, 1, 4)) which means that
the variation difference between extraction methods (PLE and US)
is not signiﬁcant. The slope, intercept and respective variances of
both curves were calculated by the ordinary least squares method.
Based on the results it was possible to conclude that PLE and US
extraction methods gave equivalent responses for this analyte. In
other words, matrix effects between these sample preparation
methods are similar. In practical terms, it is possible to use a
calibration curve prepared by US to quantify samples prepared by
both methods or conversely. Similar behaviour was observed for
other sulfonamides. Notwithstanding, a group of analytes was
considered statistically distinct. Results are shown in Table 1.
3.5. Slope ratio and mathematical model for slopes comparison
Using Eqs. (1)–(3), quantitative values for ME and recovery
were obtained (see Table 2). The slopes obtained in the calibration
curve using matrix-matched samples were compared with the
values obtained with standards in pure solvent. Besides the
equations, slope ratio was calculated for each pair of curves to
the 17 SAs included in the experiment. In this case, an acceptable
range must be previously established. In the present study, a range
from 0.9 to 1.1 was selected as lower and upper limits, respectively.
The data were also demonstrated in Table 2.
As can be observed, using Eqs. (1)–(3), ME was very high
varying from 9.4 to 73.5 % to PLE method and from 8.5 to 76.2%
when US method was applied. That means an ion suppression
extension as high as 91.6% in the case of SIZ, for instance. In
general terms, both PLE and US methods presented very intense
and highly similar ME. The use of slope ratio with acceptance
limits of 0.9–1.1 shows agreement with the data obtained using
the equations: an extremely intense ME for both PLE and US
methods and a high degree of agreement between ME produced
by PLE and US methods. When slopes of R and TS curves, some
analytes showed a ratio value between tolerance range indicating
no signiﬁcant difference between those curves. The only analyte
that showed a selective behaviour was SCA, which was the
sulfonamide that suffered less effects of the matrix.
3.6. Quantitative estimation
Several degrees of ME were demonstrated, highlighting the
huge variability among matrices. Depending on matrix nature, co-
extractives can produce ion suppression or enhancement. For
instance, Table 3 shows the quantitative ME data for some
sulfonamides in ﬁsh and eggs. In the case of ﬁsh method, ME is
present in the range of 30 to 40% of signal losses. RE and RER were
in the ranges 25–41% and 46–79%, respectively. In other words,
only ME can be responsible for approximately half of losses, if
recovery will be considered as losses of extraction method plus
Fig. 2. Calibration curves comparison for ME evaluation: similar slopes, non-
similar intercepts. Continuous line is S curve; dashed line is a TS curve and grey
line represents an R curve.
Fig. 3. Calibration curves comparison for ME evaluation: non-similar slopes.
Continuous line is S curve; dashed line is a TS curve and grey line represents an
R curve.
Fig. 4. Calibration curves comparison for ME evaluation: absence of ME. Contin-
uous line is S curve; dashed line is a TS curve and dotted line represents an R curve.
Table 1
F-test results for equality of variances between matrix-matched calibration curves prepared by PLE or US methods. Ftab¼12.22 (0.05, 1, 4).
SMR SMZ SMA SMPZ SDZ SPY SDMX SCA SMTZ SQX STZ SIZ SDX N4-SMR
Fcal 0.10 3.76 11.42 26.79 56.73 167.26 213.88 3.04 49.27 5.03 565.65 1.51 1.17 2.06
Ftab 12.22 12.22 12.22 12.22 12.22 12.22 12.22 12.22 12.22 12.22 12.22 12.22 12.22 12.22
Results FcaloFtab FcaloFtab FcaloFtab Fcal4Ftab Fcal4Ftab Fcal4Ftab Fcal4Ftab FcaloFtab Fcal4Ftab FcaloFtab Fcal4Ftab FcaloFtab FcaloFtab FcaloFtab
Variation not
signiﬁcant
True True True False False False False True False True False True True True
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losses by ion suppression. In the case of eggs, matrix is character-
ized by the intense presence of phospholipids, which are also
related with a highly intense ME, causing analytes losses from 95
to 97% [40]. However, in the case of sulfonamides in eggs,
recoveries were satisfactory, from 80 to 102%. The selected cases
demonstrate a common proﬁle of ME (ﬁsh) besides an extreme
case (eggs), but are useful to exemplify the co-existence between
intense ME and high recovery values (480%). The data corrobo-
rate that ME is independent of the recovery. For the eggs case,
another extraction protocols should be evaluated, in order to
remove the co-extractives [32].
3.7. ME continuous monitoring using control charts
The estimation of the ME during a validation procedure is
mandatory, because it is used for several matrices more or less
distinct those used during validation. A method for ME behavior
monitoring intra-batch and inter-batch will be always necessary.
Moreover, monitoring itself is not the complete task: if ME are
changing, QC samples must reﬂect this change and procedures to
assess these modiﬁcations must be available to the analyst.
Using the same kind of QC samples (S, R and TS) in every batch,
all necessary information about the method accuracy will be
available at any moment, for any batch. Accuracy data for QC
samples will provide data to build a control chart to monitor ME,
recovery and method accuracy.
Control charts are very useful tools to monitor analytical
methods behaviour. Over time, minor and major changes were
naturally occurring in routine methods. Thus, ME could be suffer-
ing changes and method adjustments will be necessary to
guarantee the adequate ﬁtness to purpose. For ME monitoring,
quality control samples were inserted in each analysis batch and
the results were calculated according to the quantitative ME
estimation. Control charts present lower and upper limits. These
limits are based on the standard deviation observed in the series.
Lower and upper limits can be used as warning limits (using the
average multiplied by 2 times the standard deviation), to observe
trends in the results and apply preventive action before the
method exceed the upper or lower limits based in 3 standard
deviation values.
Acceptance criteria follow those described in 2002/657/EC
Commission Decision and Brazilian analytical quality assurance
guidelines [11,41]. To evaluate accuracy obtained by routine data, a
critical analysis of QC samples results is performed for every batch
in accordance with limits showed in Table 4.
QC samples data (n¼3 by batch) were plotted on control charts
and critically analyzed. Results for each routine analysis should be
reviewed, and in case of non-compliance with criteria, it must be
recorded. For a batch, if the review of QC samples shows non-
Table 2
Relative (RER) and absolute recoveries (RE), matrix effect (ME) estimated using slopes data for PLE and USE extraction methods for sulfonamides analysis in liver.
SMR SMZ SMA SMPZ SDZ SPY SDMX SGA SCA SBZ SIM SMTZ SQX STZ SIZ SDX N4-SMR
PLE
RE (%) 8.8 8.1 4.7 7.6 6.0 7.8 8.3 4.2 25.2 1.5 9.2 3.0 5.0 6.7 3.0 11.7 13.9
ME (%) 23.9 25.7 13.5 28.7 16.4 24.1 29.3 12.9 73.5 6.7 30.8 19.2 20.0 11.3 9.4 34.7 24.5
RER (%) 36.7 31.5 35.1 26.5 36.5 32.6 28.2 32.7 34.4 23.0 29.8 15.5 25.3 59.2 31.5 33.7 56.8
USE
RE (%) 13.0 14.2 7.7 13.2 11.6 15.8 12.8 5.1 33.5 2.4 15.1 4.5 8.7 8.1 3.9 19.6 16.6
ME (%) 21.7 23.6 13.5 23.9 20.3 28.0 24.8 16.5 76.2 4.4 25.0 20.8 17.8 23.0 8.5 32.2 25.8
RER (%) 59.9 60.1 57.2 55.3 57.4 56.5 51.6 31.2 43.9 54.1 60.3 21.7 48.9 35.4 46.3 60.7 64.3
PLE slope ratio
TS/S 0.24 0.26 0.13 0.29 0.16 0.24 0.29 0.13 0.73 0.07 0.31 0.19 0.20 0.11 0.09 0.35 0.25
R/S 0.09 0.08 0.05 0.08 0.06 0.08 0.08 0.04 0.25 0.02 0.09 0.03 0.05 0.07 0.03 0.12 0.14
R/TS 0.37 0.31 0.35 0.26 0.37 0.33 0.28 0.33 0.34 0.23 0.30 0.16 0.25 0.59 0.32 0.34 0.57
USE slope ratio
TS/S 0.22 0.24 0.13 0.24 0.20 0.28 0.25 0.16 0.76 0.04 0.25 0.21 0.18 0.23 0.09 0.32 0.26
R/S 0.13 0.14 0.08 0.13 0.12 0.16 0.13 0.05 0.33 0.02 0.15 0.05 0.09 0.08 0.04 0.20 0.17
R/TS 0.60 0.60 0.57 0.55 0.57 0.56 0.52 0.31 0.44 0.54 0.60 0.22 0.49 0.35 0.46 0.61 0.64
Ratio USE/PLE
R/R 1.49 1.75 1.63 1.74 1.94 2.02 1.55 1.22 1.33 1.55 1.64 1.51 1.73 1.22 1.33 1.67 1.19
TS/TS 0.91 0.92 1.00 0.83 1.24 1.16 0.85 1.28 1.04 0.66 0.81 1.08 0.89 2.04 0.91 0.93 1.05
Table 3
ME quantitative estimation for sulfonamides residue analysis in ﬁsh and eggs (n¼3 for each value).
Sample type Sulfonamides in ﬁsh (peak area) Sulfonamides in eggs (peak area)
SMR SMZ SMA STZ SMZ SQX
A Standard in solvent 6.43Eþ05 4.09Eþ05 4.88Eþ05 7.01Eþ06 3.39Eþ06 7.56Eþ06
B Matrix-matched 3.46Eþ05 2.56Eþ05 2.53Eþ05 2.56Eþ05 1.29Eþ05 2.49Eþ05
C Spiked sample 1.59Eþ05 1.66Eþ05 2.00Eþ05 2.14Eþ05 1.22Eþ05 2.19Eþ05
Equation
ME(%)¼(B/A100)100 46 37 48 96 96 97
RER(%)¼C/B100 46 65 79 84 95 88
RE(%)¼(MERR)/100 25 41 41 3 4 3
ME¼matrix effects; RE¼Recovery; RER¼Relative recovery.
Table 4
Accuracy acceptability criteria.
Concentration level Range
r1 mg kg1 50aþ20%
41 mg kg1 ao10 mg kg1 30aþ10%
Z10 mg kg1 20aþ10%
R.B. Hoff et al. / Talanta 132 (2015) 443–450448
compliances in relation to acceptance criteria, appropriate correc-
tive actions must be taken. Fig. 5 shows an example for ME
monitoring to a sulfonamide residue analysis in liver samples. In
that example, data of ME (in %) for SDZ obtained from 20 batches
were plotted. The central limit (CL) was 46.4%, with an average
standard deviation of 2.6%. Lower and upper control limits were
obtained by adding or reducing the standard deviation value
(multiplied by 2 or 3) from CL.
3.8. General remarks: Matrix effect assessment in routine methods
Concisely, in our laboratory, the following workﬂow is used to
evaluate, minimize and monitor ME:
i. In method development, qualitative and/or quantitative
approaches for ME determination can be used for analytes
and surrogates/internal standards: the results can help to
decide what kind of calibration curve could be used, depend-
ing on the extension of ME observed.
ii. Extraction protocols can be modiﬁed or improved to avoid co-
extraction of matrix compounds: a SPE method could be more
adequate than LLE, for instance. Different solvents or solvent
mix can be critical to minimize ME.
iii. Once ME is observed, the post-infusion protocol is used to
determine in what chromatogram region the suppression occurs.
iv. Mobile phase gradient and/or additives can be modiﬁed in
order to provide analytes elution in a region with absence of
suppression. Generally, just simple changes in the gradient
composition are adequate to promote separation of the ana-
lytes elution window form zones with intense signal suppres-
sion. In extreme cases, solvent and even column change could
be necessary.
v. Extract injection volume can be reduced in order to decrease
ME, except when the analyte responses does reduce in the
same extent.
vi. Evaluate the effect of surrogate/internal standards in the
correction of ME.
vii. If even with these changes, ME still remain relevant, the
magnitude of the effect can be monitored during routine
analysis, using an accuracy control chart.
In validation data, a differentiation between recovery and ME
must be clear. In mass spectrometry analysis, recovery can be
deeply affected by ME although the sample preparation process
showed high efﬁciency. As ME directly affects the yield of analytes
ionization, method overall recovery have a correlation with the ME
extension. In the present work, we refer to the IUPAC’s recovery
concept, which is the analyte yield obtained after the extraction
procedure [42]. The “apparent recovery”, according to IUPAC, is the
degree of agreement between the nominated and calculated con-
centration. We use the term “relative recovery” to express the
recovery value discounting the ME. Relative recovery represents the
analyte losses caused only by the extraction procedure. Thus, this
term should not be confused with the term “apparent recovery”.
Summarizing, recovery includes losses of target compounds
throughout the whole sample preparation process (extraction,
concentration, derivatization, etc) plus the eventual ME. RER is
the loss of analytes caused by the sample preparation but not
include the ME.
Several approaches were considered to ME evaluation. Clearly,
the methods that can be used before the method validation are
more useful. The obtained data can be used to make changes or
adjustments in the extraction and/or chromatography conditions
to avoid or minimize the impact of ion suppression/enhancement.
Once adequate conditions were established, remaining ME could
be estimate using a simple approach as those based in calibration
curves or QC samples. If ME is relevant in a routine method, ME
could be monitored using a control chart in order to detect
advance changes in method behaviour.
4. Conclusions
ME is a very frequent issue in bioanalytical methods, especially in
LC–MS and LC–MS/MS based methods. Despite the fact that currently
there are no established acceptable limits for ME, it is a consensus that
their magnitude must be estimated and, if possible, minimized. Thus,
analytes extraction procedures and/or chromatographic conditions
changes could be carried out. In literature, several approaches to
estimate MEwere reported. Herein, we report our experience with ME
estimation, minimization and continuous monitoring, applying several
ME estimation strategies for analytical methods which are used in
routine analysis in our laboratory. Each technique was discussed and
their advantages and/or drawbacks were appointed, in order to
provide a practical guide for researchers interested in assessment of
ME. Based on the experience with these several techniques, the ME
evaluation must be performed before the validation, using the
quantitative estimation and post-column infusion, concomitantly.
Using this procedure, all necessary changes and adjustments could
be assessed before the validation process, improving the quality of the
results and overcoming the undesirable ME.
Fig. 5. Plot for matrix effects monitoring for sulfadiazine determination in liver. ME¼Matrix effect; CL¼central limit; UCL (2SD)¼upper control limit based on 2 standard
deviation; UCL¼upper control limit; LCL (2SD)¼ lower control limit based on 2 standard deviation; LCL¼ lower control limit.
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